VPS20.1 Antibody

What is VPS20/CHMP6 and what cellular processes does it participate in?

VPS20 (also known as CHMP6 in humans) is a critical component of the ESCRT-III complex involved in multiple cellular membrane remodeling processes. Research has established that VPS20/CHMP6 participates in:

• Multivesicular endosome biogenesis

• Cytokinesis

• Retroviral budding

• Plasma membrane repair

VPS20 functions as the primary link between ESCRT-II and other ESCRT-III components, specifically interacting with the VPS25 subunit of ESCRT-II through its first helix region . Unlike other ESCRT-III subunits, VPS20 exhibits an open, extended conformation rather than a closed, autoinhibited architecture, which appears tailored for its specific function in ESCRT-mediated membrane reorganization .

What applications are recommended for VPS20/CHMP6 antibodies in cellular research?

Based on validated research protocols, VPS20/CHMP6 antibodies can be effectively utilized in multiple experimental approaches:

Beyond these standard applications, VPS20/CHMP6 antibodies have proven valuable for:

• Affinity purification of protein complexes for mass spectrometry analysis

• Size exclusion chromatography followed by immunoblotting to analyze complex formation

• Confirming protein-protein interactions through co-immunoprecipitation studies

For optimal results, researchers should validate each antibody for their specific application and cell type, as performance may vary between experimental systems.

How should researchers select between polyclonal and monoclonal VPS20/CHMP6 antibodies?

Selection between polyclonal and monoclonal antibodies depends on your experimental goals. Polyclonal antibodies against VPS20/CHMP6, such as those raised in rabbits against recombinant proteins, offer several advantages for certain applications :

• Recognition of multiple epitopes, increasing detection sensitivity

• Greater tolerance to minor protein denaturation

• Effectiveness across a broader range of applications

For example, polyclonal antibodies raised against the ESCRT-II complex (including its interaction with VPS20) have successfully been used to study protein interactions in C. elegans extracts . These antibodies were generated by immunizing rabbits with strep-tagged intact ESCRT-II complex and subsequently affinity-purified using the same recombinant complex .

What is different about VPS20/CHMP6 compared to other ESCRT-III proteins?

VPS20/CHMP6 has several distinctive characteristics that differentiate it from other ESCRT-III proteins:

The unique structural properties of VPS20 appear specifically tailored for its function as an initiator of ESCRT-III assembly at membrane sites. Its myristoylation at the N-terminus in both yeast and human cells enhances membrane association . Together with ESCRT-II, VPS20 binds membranes with nanomolar affinity .

How should VPS20/CHMP6 antibodies be stored and handled for optimal performance?

For maximum stability and performance of VPS20/CHMP6 antibodies, researchers should follow these evidence-based recommendations:

• Store antibodies at -20°C for long-term preservation

• For short-term use, store at 4°C

• If small volumes become trapped in the cap during shipping or storage, briefly centrifuge the vial on a tabletop centrifuge

• For antibodies supplied in buffer containing preservatives like Thimerosal (0.01%), be aware of potential interactions with your experimental system

• Pay attention to specific formulation details, such as antibodies supplied in 0.1M Tris-buffered saline with 10% Glycerol (pH7.0)

Regular validation of antibody performance is recommended, especially following prolonged storage or multiple freeze-thaw cycles.

How can researchers use VPS20/CHMP6 antibodies to study ESCRT-III assembly dynamics?

Investigating ESCRT-III assembly dynamics requires sophisticated approaches that combine antibodies with complementary techniques:

Research has demonstrated that VPS20 exhibits an open, extended conformation irrespective of ESCRT-II binding, in contrast to the closed, autoinhibited architecture of VPS-24 . This conformational property can be exploited in studies focusing on the initiation of ESCRT-III assembly.

For time-resolved studies, researchers can implement pulse-chase immunoprecipitation to capture assembly intermediates at defined time points. This is particularly relevant as research indicates that ESCRT-II and VPS20 can interact directly in solution but are rapidly recruited onto membranes following their co-assembly .

What are robust methods for validating VPS20/CHMP6 antibody specificity?

Ensuring antibody specificity is critical for obtaining reliable data. Advanced validation approaches include:

• Immunoprecipitation followed by multidimensional protein identification technology (MudPIT) to confirm pulled-down proteins

• Using extracts from cells depleted of VPS20/CHMP6 as negative controls

• Comparative analysis using antibodies targeting different epitopes of VPS20/CHMP6

• Preabsorption tests with recombinant VPS20/CHMP6 protein to confirm specific binding

Research demonstrates the importance of such validation - for example, ESCRT-II antibodies were validated using extracts from wild-type animals and those depleted of all three ESCRT-II subunits . When developing experimental protocols with new antibodies, including recombinant protein standards at known concentrations can help establish detection limits and linearity ranges.

How can researchers distinguish between membrane-bound and cytosolic pools of VPS20/CHMP6?

Differentiating between membrane-associated and soluble pools of VPS20/CHMP6 requires specialized approaches:

• Perform subcellular fractionation followed by immunoblotting with VPS20/CHMP6 antibodies

• Compare immunoprecipitation results from detergent-containing extracts versus cytosolic extracts prepared by high-speed centrifugation (50,000 RPM)

• Apply size exclusion chromatography to cytosolic extract followed by immunoblotting to analyze complex formation

Research shows that ESCRT-II/VPS-20 interactions are significantly stronger in membrane-containing extracts compared to cytosolic extracts, highlighting the importance of membrane association for complex stability . In one study, treatment of low-speed supernatant with detergent prior to ESCRT-II immunoprecipitation reduced the interaction between ESCRT-II and VPS-20, suggesting that membranes stabilize their association .

Interestingly, when examining GFP-tagged Vps20 with mutations that abrogate ESCRT-II binding, the localization to both punctate structures and cytosol was essentially identical to wild-type, indicating that ESCRT-II binding is not necessary for Vps20's membrane association .

What strategies can overcome cross-reactivity issues when studying VPS20/CHMP6 in ESCRT complexes?

When studying ESCRT complexes containing multiple related proteins, researchers can minimize cross-reactivity through:

• Using antibodies raised against recombinant proteins rather than peptides for greater specificity

• Affinity purification of antibodies using the specific target protein

• Implementing reciprocal co-immunoprecipitation approaches to confirm interactions

• Designing competitive binding assays to distinguish between specific and non-specific interactions

For example, successful antibodies against the ESCRT-II complex were raised in rabbits using a strep-tagged form of the intact ESCRT-II complex and subsequently affinity-purified using the same recombinant complex . This approach increases specificity while maintaining sensitivity.

For recombinant protein production to generate antibodies or for use as standards, researchers have successfully employed several expression systems:

• Bacterial expression using pGEX6P-1 for GST-tagged proteins and His-Sumo-pET28d for His-Sumo-tagged proteins

• Purification using glutathione agarose beads (for GST-tagged proteins) or nickel affinity resin (for His-tagged proteins)

How can VPS20/CHMP6 antibodies be used to investigate protein conformational states?

The conformational dynamics of ESCRT-III components can be studied using antibodies in combination with structural techniques:

• Circular dichroism studies of purified proteins can be correlated with antibody binding to specific epitopes

• Light scattering coupled with size-exclusion chromatography can determine the molecular weight and oligomeric state of protein complexes

• Comparative immunoprecipitation under different conditions can reveal conformation-dependent interactions

Research using these approaches has revealed that individual ESCRT-III subunits adopt distinct conformations tailored for their specific functions. For example, VPS-20 exhibits an open, extended conformation, irrespective of ESCRT-II binding, in contrast with the closed, autoinhibited architecture of VPS-24 .

Understanding these conformational states is crucial as they directly impact function - VPS20 plays a key role in initiating ESCRT-III assembly, and its "ready-to-act" extended conformation may facilitate rapid response to incoming signals from ESCRT-II.